Laryngeal cancer surgery
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Omer Kamal, M.D.[2]
Overview
Overview
The feasibility of surgery depends on the stage of laryngeal cancer at the time of diagnosis. The goal of treatment is to completely remove the tumor, achieve tumor free margins and prevent the spread. The options of surgery can be transoral laser surgery, transoral robotic surgery, total laryngectomy, and total laryngectomy with partial pharyngectomy
Surgery
Surgery
The goal of treatment is to completely remove the tumor, achieve tumor free margins and prevent the spread. The following options of surgery can be considered on a case by case basis:
- Transoral laser surgery [1][2]
- Transoral robotic surgery [3][4]
- Total laryngectomy[5]
- Total laryngectomy with partial pharyngectomy [6][7]
References
References
- ↑ Ambrosch P (April 2007). “The role of laser microsurgery in the treatment of laryngeal cancer”. Curr Opin Otolaryngol Head Neck Surg. 15 (2): 82–8. doi:10.1097/MOO.0b013e3280147336. PMID 17413407.
- ↑ Zeitels SM, Burns JA (December 2014). “Oncologic efficacy of angiolytic KTP laser treatment of early glottic cancer”. Ann. Otol. Rhinol. Laryngol. 123 (12): 840–6. doi:10.1177/0003489414538936. PMID 24970297.
- ↑ Mendelsohn AH, Remacle M, Van Der Vorst S, Bachy V, Lawson G (January 2013). “Outcomes following transoral robotic surgery: supraglottic laryngectomy”. Laryngoscope. 123 (1): 208–14. doi:10.1002/lary.23621. PMID 23008093.
- ↑ Lallemant B, Chambon G, Garrel R, Kacha S, Rupp D, Galy-Bernadoy C, Chapuis H, Lallemant JG, Pham HT (October 2013). “Transoral robotic surgery for the treatment of T1-T2 carcinoma of the larynx: preliminary study”. Laryngoscope. 123 (10): 2485–90. doi:10.1002/lary.23994. PMID 23918439.
- ↑ Wolf GT, Fisher SG, Hong WK, Hillman R, Spaulding M, Laramore GE, Endicott JW, McClatchey K, Henderson WG (June 1991). “Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer”. N. Engl. J. Med. 324 (24): 1685–90. doi:10.1056/NEJM199106133242402. PMID 2034244.
- ↑ Lefebvre JL, Andry G, Chevalier D, Luboinski B, Collette L, Traissac L, de Raucourt D, Langendijk JA (October 2012). “Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891”. Ann. Oncol. 23 (10): 2708–14. doi:10.1093/annonc/mds065. PMID 22492697.
- ↑ Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T (July 1996). “Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group”. J. Natl. Cancer Inst. 88 (13): 890–9. PMID 8656441.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH